Celldex Therapeutics Inc. (CLDX): Price and Financial Metrics
CLDX Price/Volume Stats
| Current price | $26.24 | 52-week high | $48.40 |
| Prev. close | $26.26 | 52-week low | $25.66 |
| Day low | $25.66 | Volume | 325,500 |
| Day high | $26.38 | Avg. volume | 509,177 |
| 50-day MA | $31.28 | Dividend yield | N/A |
| 200-day MA | $36.82 | Market Cap | 1.24B |
CLDX Stock Price Chart Interactive Chart >
CLDX POWR Grades
- Growth is the dimension where CLDX ranks best; there it ranks ahead of 24.31% of US stocks.
- The strongest trend for CLDX is in Quality, which has been heading down over the past 179 days.
- CLDX's current lowest rank is in the Stability metric (where it is better than 9.82% of US stocks).
CLDX Stock Summary
- The ratio of debt to operating expenses for CELLDEX THERAPEUTICS INC is higher than it is for about merely 7.49% of US stocks.
- CLDX's price/sales ratio is 390.72; that's higher than the P/S ratio of 98.95% of US stocks.
- Revenue growth over the past 12 months for CELLDEX THERAPEUTICS INC comes in at 295.02%, a number that bests 97.71% of the US stocks we're tracking.
- Stocks that are quantitatively similar to CLDX, based on their financial statements, market capitalization, and price volatility, are CRNX, FDMT, IGMS, RNA, and AEVA.
- CLDX's SEC filings can be seen here. And to visit CELLDEX THERAPEUTICS INC's official web site, go to www.celldex.com.
CLDX Valuation Summary
- CLDX's price/sales ratio is 390.7; this is 20463.16% higher than that of the median Healthcare stock.
- CLDX's EV/EBIT ratio has moved up 3 over the prior 243 months.
Below are key valuation metrics over time for CLDX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CLDX | 2023-09-18 | 390.7 | 4.6 | -11.2 | -11.0 |
| CLDX | 2023-09-15 | 405.8 | 4.8 | -11.7 | -11.5 |
| CLDX | 2023-09-14 | 409.7 | 4.8 | -11.8 | -11.6 |
| CLDX | 2023-09-13 | 398.1 | 4.7 | -11.5 | -11.2 |
| CLDX | 2023-09-12 | 401.2 | 4.7 | -11.5 | -11.3 |
| CLDX | 2023-09-11 | 399.7 | 4.7 | -11.5 | -11.3 |
CLDX Growth Metrics
- Its year over year revenue growth rate is now at -22.94%.
- Its 5 year net cashflow from operations growth rate is now at 60.06%.
- The year over year net income to common stockholders growth rate now stands at -20.93%.
The table below shows CLDX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 1.078 | -96.493 | -105.986 |
| 2022-06-30 | 0.824 | -77.673 | -99.654 |
| 2022-03-31 | 4.141 | -67.359 | -77.023 |
| 2021-12-31 | 4.651 | -60.909 | -70.511 |
| 2021-09-30 | 8.103 | -51.597 | -72.263 |
| 2021-06-30 | 8.618 | -47.086 | -66.035 |
CLDX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CLDX has a Quality Grade of D, ranking ahead of 19.92% of graded US stocks.
- CLDX's asset turnover comes in at 0.038 -- ranking 340th of 682 Pharmaceutical Products stocks.
- CALA, CYRX, and BDSI are the stocks whose asset turnover ratios are most correlated with CLDX.
The table below shows CLDX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.038 | 1 | -0.480 |
| 2021-03-31 | 0.022 | 1 | -0.447 |
| 2020-12-31 | 0.034 | 1 | -0.479 |
| 2020-09-30 | 0.024 | 1 | -0.470 |
| 2020-06-30 | 0.028 | 1 | -0.636 |
| 2020-03-31 | 0.038 | 1 | -0.864 |
CLDX Price Target
For more insight on analysts targets of CLDX, see our CLDX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $64.83 | Average Broker Recommendation | 1.25 (Strong Buy) |
Celldex Therapeutics Inc. (CLDX) Company Bio
Celldex Therapeutics Inc is a biopharmaceutical company. Celldex was formed in 2005 from a spin-off of the New Jersey based biopharmaceutical company Medarex. The company is engaged in the development and commercialization of immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. Celldex is dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. The company’s drug pipeline includes antibody-based therapeutics which can engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. The company is headquartered in Hampton, New Jersey and has other operational facilities in Massachusetts and Connecticut. Anthony S. Marucci, one of Celldex’s founders, serves as Chief Executive Officer, President, and Director.
Latest CLDX News From Around the Web
Below are the latest news stories about CELLDEX THERAPEUTICS INC that investors may wish to consider to help them evaluate CLDX as an investment opportunity.
Wells Fargo starts Celldex at underweight, cites over-optimism for hives drugMore on Celldex |
AppLovin upgraded, Genpact downgraded: Wall Street's top analyst callsAppLovin upgraded, Genpact downgraded: Wall Street's top analyst calls |
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue EstimatesCelldex (CLDX) delivered earnings and revenue surprises of 0% and 60%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update- Phase 2 CSU enrollment completed; topline data by YE 2023 - - Phase 1b PN data in Q4 2023 -- First patient dosed in Phase 2 EoE study - HAMPTON, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. “Last month, we announced that enrollment in our Phase 2 chronic spontaneous urticaria trial was completed well ahead of schedule, exceeding projections by nearly |
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous UrticariaHAMPTON, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company’s Phase 2 clinical study of barzolvolimab for the treatment of chronic spontaneous urticaria (CSU). Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for the function and survival of the mast cell. CSU is |
CLDX Price Returns
| 1-mo | -9.92% |
| 3-mo | -26.06% |
| 6-mo | -28.23% |
| 1-year | -8.83% |
| 3-year | 110.76% |
| 5-year | 311.61% |
| YTD | -41.13% |
| 2022 | 15.35% |
| 2021 | 120.55% |
| 2020 | 685.65% |
| 2019 | -25.67% |
| 2018 | -92.96% |
Continue Researching CLDX
Here are a few links from around the web to help you further your research on Celldex Therapeutics Inc's stock as an investment opportunity:Celldex Therapeutics Inc (CLDX) Stock Price | Nasdaq
Celldex Therapeutics Inc (CLDX) Stock Quote, History and News - Yahoo Finance
Celldex Therapeutics Inc (CLDX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...